Friedel David, Stavropoulos Stavros, Iqbal Shahzad, Cappell Mitchell S
David Friedel, Stavros Stavropoulos, Shahzad Iqbal, Division of Gastroenterology, Winthrop Medical Center, Mineola, NY 11501, United States.
World J Gastrointest Endosc. 2014 May 16;6(5):156-67. doi: 10.4253/wjge.v6.i5.156.
About 20000 gastrointestinal endoscopies are performed annually in America in pregnant women. Gastrointestinal endoscopy during pregnancy raises the critical issue of fetal safety in addition to patient safety. Endoscopic medications may be potentially abortifacient or teratogenic. Generally, Food and Drug Administration category B or C drugs should be used for endoscopy. Esophagogastroduodenoscopy (EGD) seems to be relatively safe for both mother and fetus based on two retrospective studies of 83 and 60 pregnant patients. The diagnostic yield is about 95% when EGD is performed for gastrointestinal bleeding. EGD indications during pregnancy include acute gastrointestinal bleeding, dysphagia > 1 wk, or endoscopic therapy. Therapeutic EGD is experimental due to scant data, but should be strongly considered for urgent indications such as active bleeding. One study of 48 sigmoidoscopies performed during pregnancy showed relatively favorable fetal outcomes, rare bad fetal outcomes, and bad outcomes linked to very sick mothers. Sigmoidoscopy should be strongly considered for strong indications, including significant acute lower gastrointestinal bleeding, chronic diarrhea, distal colonic stricture, suspected inflammatory bowel disease flare, and potential colonic malignancy. Data on colonoscopy during pregnancy are limited. One study of 20 pregnant patients showed rare poor fetal outcomes. Colonoscopy is generally experimental during pregnancy, but can be considered for strong indications: known colonic mass/stricture, active lower gastrointestinal bleeding, or colonoscopic therapy. Endoscopic retrograde cholangiopancreatography (ERCP) entails fetal risks from fetal radiation exposure. ERCP risks to mother and fetus appear to be acceptable when performed for ERCP therapy, as demonstrated by analysis of nearly 350 cases during pregnancy. Justifiable indications include symptomatic or complicated choledocholithiasis, manifested by jaundice, cholangitis, gallstone pancreatitis, or dilated choledochus. ERCP should be performed by an expert endoscopist, with informed consent about fetal radiation risks, minimizing fetal radiation exposure, and using an attending anesthesiologist. Endoscopy is likely most safe during the second trimester of pregnancy.
在美国,每年约有20000例针对孕妇的胃肠道内镜检查。孕期进行胃肠道内镜检查除了涉及患者安全外,还引发了胎儿安全这一关键问题。内镜用药可能具有潜在的堕胎或致畸作用。一般来说,内镜检查应使用美国食品药品监督管理局(FDA)分类为B类或C类的药物。根据两项分别针对83例和60例孕妇的回顾性研究,食管胃十二指肠镜检查(EGD)对母亲和胎儿似乎相对安全。当EGD用于诊断胃肠道出血时,诊断率约为95%。孕期EGD的适应证包括急性胃肠道出血、吞咽困难超过1周或内镜治疗。由于数据稀少,治疗性EGD属于试验性操作,但对于活动性出血等紧急适应证应予以强烈考虑。一项针对48例孕期乙状结肠镜检查的研究显示,胎儿结局相对良好,不良胎儿结局罕见,不良结局与病情严重的母亲有关。对于强烈适应证,包括严重急性下消化道出血、慢性腹泻、远端结肠狭窄、疑似炎症性肠病发作和潜在的结肠恶性肿瘤,应强烈考虑进行乙状结肠镜检查。关于孕期结肠镜检查的数据有限。一项针对20例孕妇的研究显示,不良胎儿结局罕见。孕期结肠镜检查一般属于试验性操作,但对于强烈适应证可予以考虑:已知结肠肿物/狭窄、活动性下消化道出血或结肠镜治疗。内镜逆行胰胆管造影(ERCP)存在胎儿辐射暴露的风险。如对近350例孕期ERCP病例的分析所示,当进行ERCP治疗时,其对母亲和胎儿的风险似乎是可接受的。合理的适应证包括有症状或复杂的胆总管结石,表现为黄疸、胆管炎、胆石性胰腺炎或胆总管扩张。ERCP应由专业内镜医师进行,要告知胎儿辐射风险,尽量减少胎儿辐射暴露,并由麻醉主治医师参与。内镜检查在妊娠中期可能最为安全。